MagSense HER2 Imaging Agent (Senior Scientific)

MagSense HER2 Imaging Agent (MSH2IA) is a molecularly targeted magnetic resonance imaging (MRI) contrast agent developed for the non-invasive detection and staging of nodal metastasis in HER2-positive breast cancer. The agent consists of superparamagnetic iron oxide nanoparticles (SPIONs) coated with PEGylated biocompatible polymers and covalently conjugated to the anti-HER2 monoclonal antibody trastuzumab. Following subcutaneous (subareolar or peritumoral) injection, MSH2IA drains into the axillary lymph nodes, where the trastuzumab moiety selectively binds to HER2-expressing metastatic breast cancer cells. The bound nanoparticles alter local magnetic fields, creating a distinct magnetic signature detectable by MRI or superparamagnetic relaxometry (SPMR), thereby allowing clinicians to differentiate metastatic lymph nodes from healthy or normally reactive ones without the need for invasive biopsies.

Brand names

MagSense HER2MagSense HER2 Imaging Agent

Other names

anti-HER2 antibody conjugated PrecisionMRX nanoparticlesanti-HER-2 antibody conjugated PrecisionMRX nanoparticlesanti-HER 2 antibody conjugated PrecisionMRX nanoparticlesanti-Her-2 PEGylated superparamagnetic iron oxide nanoparticlesanti-Her2 PEGylated superparamagnetic iron oxide nanoparticlesanti-Her 2 PEGylated superparamagnetic iron oxide nanoparticlestrastuzumab-conjugated superparamagnetic iron oxide nanoparticles